Nihon Kohden Valuation Multiples

Nihon Kohden Overview

About Nihon Kohden

Nihon Kohden Corp is a Japan-based company engaged in the development, manufacturing, and sale of medical electronic equipment. It offers monitoring and diagnostic equipment such as electroencephalographs, electrocardiographs, and patient monitors, along with related systems and consumables. The company operates as a single business segment and manages its activities comprehensively across three reportable regions: Japan, North America, and Other Regions.

Founded

1951

HQ

Employees

6.6K

Website

nihonkohden.co.jp

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $1B

EBITDA: $163M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Nihon Kohden Financials

Nihon Kohden reported last 12-month revenue of $1B and EBITDA of $163M.

In the same LTM period, Nihon Kohden generated $766M in gross profit, $163M in EBITDA, and $82M in net income.

Nihon Kohden P&L

In the most recent fiscal year, Nihon Kohden reported revenue of $2B and EBITDA of $171M.

Nihon Kohden expects next 12-month revenue of XXX and NTM EBITDA of XXX

Nihon Kohden Stock Performance

Nihon Kohden has current market cap of $2B, and enterprise value of $1B.

Nihon Kohden's stock price is $9.69.

Nihon Kohden Valuation Multiples

Nihon Kohden trades at 1.0x EV/Revenue multiple, and 8.8x EV/EBITDA.

Nihon Kohden Financial Valuation Multiples

As of April 20, 2026, Nihon Kohden has market cap of $2B and EV of $1B.

Equity research analysts estimate Nihon Kohden's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nihon Kohden has a P/E ratio of 19.0x.

Nihon Kohden Margins & Growth Rates

Nihon Kohden's revenue in the last 12 month declined by (1%).

Nihon Kohden's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Nihon Kohden's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nihon Kohden's rule of X is 13% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Nihon Kohden Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Nihon Kohden M&A Activity

Nihon Kohden acquired XXX companies to date.

Last acquisition by Nihon Kohden was on XXXXXXXX, XXXXX. Nihon Kohden acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Nihon Kohden Investment Activity

Nihon Kohden invested in XXX companies to date.

Nihon Kohden made its latest investment on XXXXXXXX, XXXXX. Nihon Kohden invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).